Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 9/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21358424 | 0.85 | ENPP1 (0.71) | ENPP1MAPK1 | |
| SCHEMBL29354481 | 0.85 | ENPP1 (0.71) | ENPP1MAPK1 | |
| SCHEMBL22407576 | 0.84 | ENPP1 (0.75) | ENPP1SIRT2SIRT1SIRT3 | |
| SCHEMBL22407463 | 0.84 | ENPP1 (0.72) | ENPP1MAPK1CYP1A2CYP2D6MTNR1B | |
| SCHEMBL22407607 | 0.83 | ENPP1 (0.62) | ENPP1MAPK1CYP1A2CYP2D6 | |
| SCHEMBL22407359 | 0.83 | ENPP1 (0.62) | ENPP1MAPK1CYP1A2CYP2D6 | |
| SCHEMBL23727319 | 0.82 | ENPP1 (0.73) | ENPP1MAPK1 | |
| SCHEMBL22407453 | 0.82 | ENPP1 (0.61) | ENPP1MAPK1 | |
| SCHEMBL22407443 | 0.82 | ENPP1 (0.61) | ENPP1MAPK1 | |
| SCHEMBL22407459 | 0.82 | ENPP1 (0.61) | ENPP1CYP1A2CYP2D6MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ENPP1 1/4885MAPK1 2004/4885CYP1A2 4167/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ENPP1 1/4885MAPK1 2004/4885CYP1A2 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.